Mapping your journey: Stages and progression of dementia

Dementia's Accelerating Burden

Canada confronts a rapidly escalating dementia crisis fueled by population aging. As of early 2025, an estimated 772,000 people live with dementia, with over 414 new cases emerging daily. Projections indicate nearly 1 million affected by 2030—a 65% rise from 2020—and 1.7 million by 2050 if trends persist.

This surge carries profound economic weight. Dementia imposed roughly $40 billion in costs in 2020, blending direct medical expenses with indirect losses from productivity and unpaid care. Family caregivers delivered 470 million hours annually, equivalent to 235,000 full-time jobs and billions in forgone income. Without shifts, caregiving demands could triple by 2050, straining families where many juggle work, finances, and health.

The landscape shifted decisively in October 2025 when Health Canada conditionally approved lecanemab for early-stage Alzheimer's, marking the first approved treatment to alter underlying disease biology rather than merely ease symptoms. Yet public drug plans face draft advice against coverage, citing unclear meaningful benefits relative to risks and expense. Access remains limited, potentially confined to those affording private payment.

Understanding progression stages matters acutely now because available therapies work best—or only—in mild cognitive impairment or early dementia phases. Brain changes precede symptoms by years; late intervention misses the narrow window where slowing plaque buildup might preserve function longer. Real-world stakes include prolonged independence, delayed institutionalization, and reduced caregiver strain, but inaction risks faster decline, higher healthcare utilization, and amplified societal costs.

Non-obvious tensions persist. Many patients exhibit mixed dementias or comorbidities, complicating stage assignment and treatment eligibility. Diagnostic delays average months to years, while emerging biomarkers promise earlier detection but heighten equity concerns if access lags. Public reluctance to fund costly therapies contrasts with private-sector momentum and global approvals elsewhere, leaving Canada trailing in equitable rollout.